Researchers developed a new mouse model that more closely captures a specific type of inflammation characteristic of progressive multiple sclerosis (MS) — and found, in experiments, that treatment with an oral medication called evobrutinib can lessen disease activity. This new mouse model may help scientists in MS to better study…

Progressive multiple sclerosis (MS) is the focus of the 2020 virtual European Multiple Sclerosis Platform (EMSP) annual meeting that runs though Friday, Nov. 20. Registration is free for the two-day conference. Those interested in participating can register here. According to a EMSP press release, topics to be discussed include the most…

One of the world’s most commonly used medications — the cholesterol-lowering drug simvastatin — was found to affect the immune system in a way that can be explored to treat inflammatory diseases such as multiple sclerosis (MS). Researchers have earlier noted that simvastatin, a cholesterol-lowering drug, is beneficial for MS…

MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…

Exploratory research conducted at Virginia Commonwealth University and the University of Illinois at Chicago may translate into a new therapeutic agent to treat progressive multiple sclerosis. Researchers in the laboratories of Dr. Jefferey L. Dupree and Dr. Douglas L. Feinstein tested a new compound in mice with induced multiple sclerosis…

While multiple sclerosis (MS) is considered a rare condition with major unmet medical needs, the treatments for progressive forms of MS are even scarcer, with no viable, FDA-approved drugs available to specifically address these forms of the disease. Because of this, the MS community is eagerly following a major…

MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of their ongoing clinical study evaluating ibudilast (MN-166) for the treatment of progressive…

MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective for treatment of progressive multiple sclerosis, according to results from a recent Phase III trial. MD1003 may have two beneficial effects: 1) increasing myelin, the fatty nerve-insulating…

As the most common non-traumatic cause of disability in young people in the industrialized world, multiple sclerosis affects more than 2.5 million people globally. Those who suffer with the disease are categorized into two types of multiple sclerosis patients: those with relapsing-remitting multiple sclerosis (RRMS) make up the majority of patients…

People with multiple sclerosis (MS) commonly experience a low pain threshold and sensitivity to heat and cold. If a person has multiple sclerosis along with fibromyalgia (FM), that could make this sensitivity even more intense. Until now, no group has studied this phenomenon. In a study titled “…

MedDay recently announced in a news release that it is preparing to release the design and results of its clinical trial to assess the safety and efficacy of MD1003 in primary and secondary progressive multiple sclerosis (MS) treatment. Data on the Phase III clinical trial (MS-SPI) will be presented…

Neurology and autoimmune therapeutics company GeNeuro SA has just announced the formation of a partnership with independent French pharmaceutical company Servier for the co-development and marketing of GNbAC1 for Multiple Sclerosis (MS). It is the first humanized monocloncal antibody treatment formulated to address one of this disease’s causal factors, making it…

54 new multiple sclerosis (MS) research and development initiatives are set to receive substantial funding in order to accelerate new therapies. The National Multiple Sclerosis Society (NMSS) announced that it has pledged $19 million to fund these new MS studies as part of their mission to better manage…

San Francisco Bay Area-based Glialogix, Inc., a biopharmaceutical company that specializes in developing novel treatments for multiple sclerosis (MS), announced yesterday that they have closed a Sponsored Research Agreement with Fast Forward, a non-profit organization that aims to accelerate MS treatment development. Glialogix will receive funding for one of their…

Deepelling International conferences on multiple sclerosis (MS) typically gather the most accomplished experts and leading biotech companies under one roof to exchange discoveries and celebrate new hope for MS patients all over the world. Quebec is one of North America’s epicenters for MS research and developments. This year, on…

The first round of 22 research grants have been awarded to projects in nine countries by the International Progressive MS Alliance, with the goal of removing barriers to developing treatments for progressive MS. The 22 projects were chosen from 195 research proposals submitted by researchers in 22 countries and…